Biotech eXithera is a portfolio company of Israel’s Clal Biotechnology. It has developed an anti-coagulant which has successfully completed Phase 1 trials. The treatment delays coagulation rather than prevents it and its effects cease quickly when the treatment stops.
https://en.globes.co.il/en/article-sichuan-haisco-invests-in-clal-biotechs-exithera-1001280424